ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

2:00PM-3:30PM: Abstract Number: 2486

Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores?

Abstracts: SLE – Treatment II: Nonrenal

2:00PM-3:30PM: Abstract Number: 2500

Suicidal Ideation and Self-Efficacy in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort

Abstracts: Interprofessional OA & Lupus

2:00PM-3:30PM: Abstract Number: 2440

Synovial Shaping of Skin-derived Migrating Immune Cells Determines Initiation of Inflammation in Psoriatic Arthritis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science

2:00PM-3:30PM: Abstract Number: 2438

Synovial Tissue Single-Cell Analysis Demonstrates Differential Fibroblast Populations Between RA and PsA Which Display Distinct Function

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science

2:00PM-3:30PM: Abstract Number: 2472

Synovitis and the Risk of Incident Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study

Abstracts: Osteoarthritis II: Novel Insights from Observational Studies

2:00PM-3:30PM: Abstract Number: 2445

Targeting of Endothelial Dysfunction in Lupus Nephritis: Effect on Human Renal Endothelial Cell Gene Expression and Outcomes in Murine Lupus Nephritis

Abstracts: SLE – Animal Models

2:00PM-3:30PM: Abstract Number: 2451

TET2 Clonal Hematopoiesis and Incident Rheumatoid Arthritis: Results from the UK Biobank

Abstracts: Epidemiology & Public Health II

2:00PM-3:30PM: Abstract Number: 2492

The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life

Abstracts: Vasculitis – ANCA-Associated II

2:00PM-3:30PM: Abstract Number: 2458

The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center

Abstracts: Healthcare Disparities in Rheumatology

2:00PM-3:30PM: Abstract Number: 2479

Tolerability and Effectiveness of Antifibrotics in Rheumatoid Arthritis-associated Interstitial Lung Disease

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Predicting & Optimizing Outcomes

2:00PM-3:30PM: Abstract Number: 2461

Transcriptional Derepression of CHD4/NuRD-regulated Genes in the Muscle of Patients with Dermatomyositis and anti-Mi2 Autoantibodies

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I

2:00PM-3:30PM: Abstract Number: 2437

Translocation of Intestinal Bacteria to Axial and Peripheral Joints in a Model of Spondyloarthropathy

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science

2:00PM-3:30PM: Abstract Number: 2495

Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis

Abstracts: Vasculitis – ANCA-Associated II

2:00PM-3:30PM: Abstract Number: 2441

Upregulation of RANKL in the Skin of Patients with Psoriatic Arthritis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science

2:00PM-3:30PM: Abstract Number: 2448

UV Light Exposure Induces a Type I Interferon Dependent Activation and Migration of Inflammatory Dendritic Cells to Local Lymph Nodes

Abstracts: SLE – Animal Models

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].